Neuroscience Education Institute

10/19/2026

Your front-row seat to psychiatry education is wherever you are. Join the 2026 NEI Fall Congress live via simulcast, November 5–8, for four days of online CME/CE for mental health professionals. Explore advances in psychopharmacology with leading experts and gain practical strategies for the clinical challenges you encounter every day.

Bring fresh perspectives to your practice, all from the comfort of your home or office.

Explore the agenda and register

Advance your psychopharmacology knowledge with live online CME/CE at NEI Fall Congress, November 5–8.

10/17/2026

NEI Saturday Morning Live is starting soon! Log in now to hear from two leading experts exploring the role of long-acting injectables in optimizing outcomes for patients with serious mental illness. Hara Oyedeji, DNP, PMHNP-BC, MSEd, and Leslie Citrome, MD, MPH, will share practical, evidence-based strategies for determining when and why to consider an LAI, selecting an appropriate formulation, and initiating and maintaining treatment. Join the conversation live and have your questions answered during the Q&A. Log in here ➡

Log in to NEI Saturday Morning Live on October 17 for a free, live CME/CE program featuring expert-led education, practical clinical insights, and an interactive Q&A. Access the event portal and join us live.

10/16/2026

Learn what’s new, what works, and how to use it! With so many long-acting injectable (LAI) formulations available, including the newly FDA-approved once-monthly subcutaneous olanzapine extended-release injectable suspension, how do you choose the right option for your patient?

Join us Saturday, October 17, for a free, half-day virtual CE program exploring when and why to consider an LAI, how to select an appropriate formulation, and practical strategies for initiating and maintaining treatment.

Register Here 👉 https://nei.global/26sml-register

10/15/2026

There’s still time to register! Join us Saturday, October 17, for a free, half-day virtual CE program exploring how long-acting injectable (LAI) formulations can help optimize outcomes for patients with serious mental illness.

Gain practical strategies for determining when and why to consider an LAI, selecting an appropriate formulation, and successfully initiating and maintaining treatment.

Register today and earn FREE CME/CE credits: https://nei.global/26sml-register

10/15/2026

Could orexin signaling open a new direction in attention-deficit/hyperactivity disorder (ADHD) treatment? Orexin-2 receptor agonism is emerging as a potential research direction in ADHD. Explore the biological rationale and preliminary findings for ALKS 7290, an investigational oral treatment. Read more

Orexin A and orexin B are neuropeptides produced by neurons concentrated in the lateral hypothalamus that project widely throughout the brain. In addition to promoting and maintaining wakefulness, the orexin system engages neural circuits involved in attention, cognition, motivation, reward, and moo...

10/13/2026

Join us this Saturday, October 17, for a free online CME/CE program exploring the role of long-acting injectables (LAIs) in optimizing treatment outcomes for patients with serious mental illness.
Hear expert insights from Hara Oyedeji, DNP, PMHNP-BC, MSEd, and Leslie Citrome, MD, MPH, and earn 2.5 CME/CE credits from the comfort of home.
Register for free 👉 https://nei.global/26sml-oct-17

10/09/2026

The U.S. Food and Drug Administration has approved the first once-monthly subcutaneous olanzapine injection for adults with schizophrenia. The new formulation requires no loading dose, oral supplementation, or post-injection monitoring. Read more:

The U.S. Food and Drug Administration (FDA) has approved olanzapine for extended-release injectable suspension for the treatment of schizophrenia in adults.

10/08/2026

Psychedelic therapeutics are making headlines. What does the evidence mean for clinical practice? At the upcoming 2026 NEI Fall Congress, Dr. Roger McIntyre will examine the promise and limitations of psilocybin, MDMA-assisted therapy, and other emerging approaches. Explore how trial design, treatment durability, safety, and regulatory decisions shape the path from research to responsible care.

Explore the science behind the headlines this November at NEI Fall Congress. Join us in person or online via simulcast.

At the 2026 NEI Fall Congress, Roger S. McIntyre, MD, FRCPC, will examine research on psilocybin for depression and substance use disorders, MDMA-assisted therapy for PTSD, and emerging approaches involving L*D, DMT, and 5-MeO-DMT.

10/07/2026

This episode of The PsychopharmaStahlogy Show features Drs. Andrew Cutler and Stephen Stahl in conversation with Dr. Tiffany Greenwood on the genetic and trait-based links between bipolar disorder and creativity. They explore how temperament, personality, and cognitive style may occupy the space between madness and genius, the role of dopamine, evolutionary explanations for why bipolar risk persists, and why stabilizing mood doesn't have to mean losing creativity. Listen now:

This episode of The PsychopharmaStahlogy Show features Drs. Andrew Cutler and Stephen Stahl in conversation with Dr. Tiffany Greenwood on the genetic and trait-based links between bipolar disorder and creativity. They explore how temperament, personality, and cognitive style may occupy the space bet...

10/06/2026

The U.S. Food and Drug Administration (FDA) has approved tavapadon for the treatment of Parkinson disease in adults. Tavapadon is an oral, once-daily selective partial agonist at dopamine D1 and D5 receptors. It was studied without levodopa in early disease and as an adjunct to levodopa in patients with motor fluctuations. Read more

The U.S. Food and Drug Administration (FDA) has approved tavapadon for the treatment of Parkinson disease in adults. Tavapadon is an oral, once-daily selective partial agonist at dopamine D1 and D5 receptors. It was studied without levodopa in early disease and as an adjunct to levodopa in patients....